Odimma is part of the 10 new projects to be supported by the Paris Saclay Cancer Cluster

2024-12-10

We are thrilled to share that Odimma-Therapeutics has been selected as one of the successful applicants for the Paris Saclay Cancer Cluster's call for applications. This recognition underscores our commitment to innovation and ambition in addressing critical public health challenges. By leveraging cutting-edge technologies and pioneering approaches, we aim to make a meaningful impact in the fight against cancer and beyond. We are proud to join this esteemed community, working together to drive transformative advancements in healthcare.


> read the complete news